TY - JOUR T1 - Targeting triple-negative breast cancer with β1-integrin binding aptamer JF - bioRxiv DO - 10.1101/2022.07.28.501822 SP - 2022.07.28.501822 AU - Karlis Pleiko AU - Maarja Haugas AU - Vadims Parfejevs AU - Teodors Pantelejevs AU - Emilio Parisini AU - Tambet Teesalu AU - Una Riekstina Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/07/28/2022.07.28.501822.abstract N2 - Targeted therapies have increased the treatment options for triple-negative breast cancer patients. However, the paucity of targetable biomarkers and tumour heterogeneity have limited the ability of precision-guided interventions to live up to their full potential. As affinity targeting ligands, aptamers show high selectivity towards target molecules. Compared to antibodies, aptamers have lower molecular weight, increased stability during transportation, reduced immunogenicity, and increased tissue uptake. Recently, we reported the discovery of GreenB1 aptamer that is internalized in cultured triple-negative MDA-MB-231 human breast cancer cells. We show that the GreenB1 aptamer specifically targets β1-integrin, a protein previously linked to breast cancer cell invasiveness and migration. Aptamer binds to β1-integrin with low nanomolar affinity. GreenB1 homes in the orthotopic 4T1 triple-negative breast cancer lesions modelled in mice. Our findings suggest potential applications for the GreenB1-guided precision agents for the diagnosis and therapy of triple-negative breast cancer.Competing Interest StatementThe authors have declared no competing interest. ER -